203 related articles for article (PubMed ID: 24854617)
1. Chemotherapy for advanced pancreatic adenocarcinoma in elderly patients (≥70 years of age): a retrospective cohort study at the National Center for Tumor Diseases Heidelberg.
Berger AK; Abel U; Komander C; Harig S; Jäger D; Springfeld C
Pancreatology; 2014; 14(3):211-5. PubMed ID: 24854617
[TBL] [Abstract][Full Text] [Related]
2. Analysis of second-line chemotherapies for ductal pancreatic adenocarcinoma in a German single-center cohort.
Maier-Stocker C; Bitzer M; Malek NP; Plentz RR
Scand J Gastroenterol; 2014 Dec; 49(12):1480-5. PubMed ID: 25390691
[TBL] [Abstract][Full Text] [Related]
3. Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma.
Perri G; Prakash L; Qiao W; Varadhachary GR; Wolff R; Fogelman D; Overman M; Pant S; Javle M; Koay EJ; Herman J; Kim M; Ikoma N; Tzeng CW; Lee JE; Katz MHG
JAMA Surg; 2020 Sep; 155(9):832-839. PubMed ID: 32667641
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of Capecitabine Plus Oxaliplatin Combination Chemotherapy for Advanced Pancreatic Cancer after Failure of First-Line Gemcitabine-Based Therapy.
Chung KH; Ryu JK; Son JH; Lee JW; Jang DK; Lee SH; Kim YT
Gut Liver; 2017 Mar; 11(2):298-305. PubMed ID: 27965478
[TBL] [Abstract][Full Text] [Related]
5. Current Standard and Future Perspectives in First- and Second-Line Treatment of Metastatic Pancreatic Adenocarcinoma.
Ellenrieder V; König A; Seufferlein T
Digestion; 2016; 94(1):44-9. PubMed ID: 27438590
[TBL] [Abstract][Full Text] [Related]
6. Gemcitabine/nab-Paclitaxel versus FOLFIRINOX for palliative first-line treatment of advanced pancreatic cancer: A propensity score analysis.
Riedl JM; Posch F; Horvath L; Gantschnigg A; Renneberg F; Schwarzenbacher E; Moik F; Barth DA; Rossmann CH; Stotz M; Schaberl-Moser R; Pichler M; Stöger H; Greil R; Djanani A; Schlick K; Gerger A
Eur J Cancer; 2021 Jul; 151():3-13. PubMed ID: 33951545
[TBL] [Abstract][Full Text] [Related]
7. Improvement in advanced pancreatic cancer survival with novel chemotherapeutic strategies - experience of a community based hospital.
Hann A; Bohle W; Egger J; Zoller WG
Z Gastroenterol; 2016 Oct; 54(10):1138-1142. PubMed ID: 27723905
[No Abstract] [Full Text] [Related]
8. A two-cohort phase I study of weekly oxaliplatin and gemcitabine, then oxaliplatin, gemcitabine, and erlotinib during radiotherapy for unresectable pancreatic carcinoma.
Raftery L; Tepper JE; Goldberg RM; Blackstock AW; Aklilu M; Bernard SA; Ivanova A; Davies JM; O'Neil BH
Am J Clin Oncol; 2013 Jun; 36(3):250-3. PubMed ID: 22547007
[TBL] [Abstract][Full Text] [Related]
9. KRAS mutation in metastatic pancreatic ductal adenocarcinoma: results of a multicenter phase II study evaluating efficacy of cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line therapy.
Kullmann F; Hartmann A; Stöhr R; Messmann H; Dollinger MM; Trojan J; Fuchs M; Hollerbach S; Harder J; Troppmann M; Kutscheidt A; Endlicher E
Oncology; 2011; 81(1):3-8. PubMed ID: 21894049
[TBL] [Abstract][Full Text] [Related]
10. Frontline treatment with gemcitabine, oxaliplatin and erlotinib for the treatment of advanced or metastatic pancreatic cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG).
Katopodis O; Souglakos J; Stathopoulos E; Christopoulou A; Kontopodis E; Kotsakis A; Kalbakis K; Kentepozidis N; Polyzos A; Hatzidaki D; Georgoulias V
Cancer Chemother Pharmacol; 2014 Aug; 74(2):333-40. PubMed ID: 24930058
[TBL] [Abstract][Full Text] [Related]
11. Short time to progression under first-line chemotherapy is a negative prognostic factor for time to progression and residual survival under second-line chemotherapy in advanced pancreatic cancer.
Herrmann C; Abel U; Stremmel W; Jaeger D; Herrmann T
Oncology; 2007; 73(5-6):335-9. PubMed ID: 18497506
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of gemcitabine, oxaliplatin, and cetuximab in advanced pancreatic cancer.
Merchan JR; Ferrell A; Macintyre J; Ciombor KK; Levi J; Ribeiro A; Sleeman D; Flores A; Lopes G; Rocha-Lima CM
Am J Clin Oncol; 2012 Oct; 35(5):446-50. PubMed ID: 21552097
[TBL] [Abstract][Full Text] [Related]
13. Metastatic pancreatic cancer: old drugs, new paradigms.
Conroy T; Gavoille C; Adenis A
Curr Opin Oncol; 2011 Jul; 23(4):390-5. PubMed ID: 21505335
[TBL] [Abstract][Full Text] [Related]
14. Neutrophil-to-lymphocyte ratio for predicting palliative chemotherapy outcomes in advanced pancreatic cancer patients.
Xue P; Kanai M; Mori Y; Nishimura T; Uza N; Kodama Y; Kawaguchi Y; Takaori K; Matsumoto S; Uemoto S; Chiba T
Cancer Med; 2014 Apr; 3(2):406-15. PubMed ID: 24519894
[TBL] [Abstract][Full Text] [Related]
15. [Chemotherapy of pancreatic carcinoma].
Lutz MP
Praxis (Bern 1994); 2005 Jun; 94(22):933-5. PubMed ID: 15986638
[TBL] [Abstract][Full Text] [Related]
16. Palliative chemotherapy for gastroesophageal cancer in old and very old patients: A retrospective cohort study at the National Center for Tumor Diseases, Heidelberg.
Berger AK; Zschaebitz S; Komander C; Jäger D; Haag GM
World J Gastroenterol; 2015 Apr; 21(16):4911-8. PubMed ID: 25945004
[TBL] [Abstract][Full Text] [Related]
17. Treatment patterns and outcomes in pancreatic cancer: Retrospective claims analysis.
Doleh Y; Lal LS; Blauer-Petersen C; Antico G; Pishvaian M
Cancer Med; 2020 May; 9(10):3463-3476. PubMed ID: 32212262
[TBL] [Abstract][Full Text] [Related]
18. Management of advanced pancreatic cancer with gemcitabine plus erlotinib: efficacy and safety results in clinical practice.
Diaz Beveridge R; Alcolea V; Aparicio J; Segura Á; García J; Corbellas M; Fonfría M; Giménez A; Montalar J
JOP; 2014 Jan; 15(1):19-24. PubMed ID: 24413779
[TBL] [Abstract][Full Text] [Related]
19. Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study.
Park SJ; Kim H; Shin K; Hong TH; Suh JH; Lee MA
BMC Cancer; 2021 Nov; 21(1):1176. PubMed ID: 34732161
[TBL] [Abstract][Full Text] [Related]
20. Metastatic Pancreatic Adenocarcinoma Treatment Patterns, Health Care Resource Use, and Outcomes in France and the United Kingdom Between 2009 and 2012: A Retrospective Study.
Smyth EN; Bapat B; Ball DE; André T; Kaye JA
Clin Ther; 2015 Jun; 37(6):1301-16. PubMed ID: 25907619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]